{"id":47269,"date":"2022-08-13T03:01:42","date_gmt":"2022-08-13T01:01:42","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\/"},"modified":"2022-08-13T03:01:42","modified_gmt":"2022-08-13T01:01:42","slug":"arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\/","title":{"rendered":"Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nAll claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied\n<\/li>\n<\/ul>\n<p>TOKYO &amp; MUNICH &amp; BASKING RIDGE, N.J.&#8211;(BUSINESS WIRE)&#8211;An arbitrator issued a decision today in a dispute between Daiichi Sankyo Company, Ltd. and Seagen, Inc., denying all claims made by Seagen. Specifically, Daiichi Sankyo retains all patent rights to its antibody drug conjugate (ADC) technology and will continue to develop and commercialize these medicines as planned.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220812005415\/en\/808160\/5\/DS_logo_portrait_format_4color_rgb_120206.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220812005415\/en\/808160\/21\/DS_logo_portrait_format_4color_rgb_120206.jpg\"><\/a><\/p>\n<p>\nIn November 2019, Daiichi Sankyo filed a Declaratory Judgment action in the District Court of Delaware against Seagen in response to communications from Seagen claiming certain intellectual property rights related to Daiichi Sankyo\u2019s ADC technology. Seagen\u2019s claims related to a collaboration agreement between the two companies from 2008 to 2015. In response, Seagen filed an arbitration demand in connection with the dispute with the American Arbitration Association in the same month, resulting in an arbitration and today\u2019s decision.\n<\/p>\n<p>\n\u201cWe are extremely pleased that, based on the facts of this matter, the arbitrator recognized that Daiichi Sankyo retains ownership of all patents at issue in the arbitration and that our platform ADC technology was developed by Daiichi Sankyo,\u201d said Sunao Manabe, President and CEO of Daiichi Sankyo, Company, Ltd. \u201cDaiichi Sankyo is proud of our legacy and strength in innovative science and technology and remains committed to bringing our ADCs to patients who need new standards of care in cancer treatment.\u201d\n<\/p>\n<p>\n<b>About Daiichi Sankyo<\/b>\n<\/p>\n<p>\nDaiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose \u201cto contribute to the enrichment of quality of life around the world.\u201d In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an \u201cInnovative Global Healthcare Company Contributing to the Sustainable Development of Society.\u201d For more information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.daiichisankyo.com&amp;esheet=52812788&amp;newsitemid=20220812005415&amp;lan=en-US&amp;anchor=www.daiichisankyo.com&amp;index=1&amp;md5=67e4ada7601ad82c0d1ef9eccd3944c6\" rel=\"nofollow noopener\" shape=\"rect\">www.daiichisankyo.com<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Global\/Japan:<\/b><br \/>Masashi Kawase<br \/>\n<br \/>Daiichi Sankyo Co., Ltd.<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;a&#x69;l&#x74;o&#x3a;k&#x61;w&#x61;s&#x65;&#46;&#x6d;&#97;&#x73;&#97;&#x73;&#104;&#x69;&#46;&#x61;&#50;&#x40;&#100;a&#x69;i&#x63;h&#x69;s&#x61;n&#x6b;y&#x6f;&#46;&#x63;&#111;&#x2e;&#106;&#x70;\" rel=\"nofollow noopener\" shape=\"rect\">&#x6b;&#x61;&#119;a&#x73;&#x65;&#46;ma&#x73;&#x61;&#115;h&#x69;&#x2e;&#97;&#50;&#64;&#x64;&#x61;&#105;i&#x63;&#x68;&#105;&#115;a&#x6e;&#x6b;&#121;o&#x2e;&#x63;&#111;&#46;j&#x70;<\/a><br \/>+81 3 6225 1126 (office)\n<\/p>\n<p>\n<b>US:<\/b><br \/>Kim Wix<br \/>\n<br \/>Daiichi Sankyo, Inc.<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;a&#x69;&#108;&#x74;&#x6f;:&#x6b;&#119;&#x69;&#x78;&#64;&#x64;&#115;&#x69;&#x2e;c&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#x6b;&#119;&#105;&#x78;&#x40;&#100;&#115;&#x69;&#x2e;&#99;&#111;&#x6d;<\/a><br \/>+1 908 656 5447 (mobile)\n<\/p>\n<p>\n<b>EU:<\/b><br \/>Simone Dowe<br \/>\n<br \/>Daiichi Sankyo Europe GmbH<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#116;&#111;&#58;&#115;imo&#x6e;&#x65;&#x2e;&#x64;&#x6f;&#119;&#101;&#64;dai&#x69;&#x63;&#x68;&#x69;&#x2d;&#115;&#97;&#110;kyo&#x2e;&#x65;&#x75;\" rel=\"nofollow noopener\" shape=\"rect\">s&#105;&#x6d;&#x6f;n&#101;&#x2e;&#x64;o&#119;&#101;&#x40;&#x64;a&#105;&#x69;&#x63;h&#105;&#x2d;&#x73;a&#110;&#107;&#x79;&#x6f;&#46;&#101;&#x75;<\/a><br \/>+49897808437 (office)<br \/>\n<br \/>+49 (176) 11780822 (mobile)\n<\/p>\n<p>\n<b>Investor Relations Contact:<\/b><br \/><a target=\"_blank\" href=\"m&#97;&#105;&#108;&#x74;&#x6f;&#x3a;Da&#105;&#105;&#x63;&#x68;&#x69;&#x53;an&#107;&#121;&#x6f;&#x49;&#x52;&#x40;d&#97;&#105;&#105;&#x63;&#x68;&#x69;sa&#110;&#107;&#121;&#x6f;&#x2e;&#x63;o&#46;&#106;&#112;\" rel=\"nofollow noopener\" shape=\"rect\">&#x44;&#x61;&#x69;&#x69;&#x63;&#x68;&#105;&#83;&#97;&#110;kyoI&#x52;&#x40;&#x64;&#x61;&#x69;&#x69;&#99;&#104;&#105;&#115;&#97;nky&#x6f;&#x2e;&#x63;&#x6f;&#x2e;&#x6a;&#112;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied TOKYO &amp; MUNICH &amp; BASKING RIDGE, N.J.&#8211;(BUSINESS WIRE)&#8211;An arbitrator issued a decision today in a dispute between Daiichi Sankyo Company, Ltd. and Seagen, Inc., denying all claims made by Seagen. Specifically, Daiichi Sankyo retains all patent rights to its antibody drug conjugate &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47269","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied TOKYO &amp; MUNICH &amp; BASKING RIDGE, N.J.&#8211;(BUSINESS WIRE)&#8211;An arbitrator issued a decision today in a dispute between Daiichi Sankyo Company, Ltd. and Seagen, Inc., denying all claims made by Seagen. Specifically, Daiichi Sankyo retains all patent rights to its antibody drug conjugate ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-13T01:01:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220812005415\/en\/808160\/21\/DS_logo_portrait_format_4color_rgb_120206.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen\",\"datePublished\":\"2022-08-13T01:01:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\\\/\"},\"wordCount\":416,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220812005415\\\/en\\\/808160\\\/21\\\/DS_logo_portrait_format_4color_rgb_120206.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\\\/\",\"name\":\"Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220812005415\\\/en\\\/808160\\\/21\\\/DS_logo_portrait_format_4color_rgb_120206.jpg\",\"datePublished\":\"2022-08-13T01:01:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220812005415\\\/en\\\/808160\\\/21\\\/DS_logo_portrait_format_4color_rgb_120206.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220812005415\\\/en\\\/808160\\\/21\\\/DS_logo_portrait_format_4color_rgb_120206.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\/","og_locale":"en_US","og_type":"article","og_title":"Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen - Pharma Trend","og_description":"All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied TOKYO &amp; MUNICH &amp; BASKING RIDGE, N.J.&#8211;(BUSINESS WIRE)&#8211;An arbitrator issued a decision today in a dispute between Daiichi Sankyo Company, Ltd. and Seagen, Inc., denying all claims made by Seagen. Specifically, Daiichi Sankyo retains all patent rights to its antibody drug conjugate ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-13T01:01:42+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220812005415\/en\/808160\/21\/DS_logo_portrait_format_4color_rgb_120206.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen","datePublished":"2022-08-13T01:01:42+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\/"},"wordCount":416,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220812005415\/en\/808160\/21\/DS_logo_portrait_format_4color_rgb_120206.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\/","url":"https:\/\/pharma-trend.com\/en\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\/","name":"Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220812005415\/en\/808160\/21\/DS_logo_portrait_format_4color_rgb_120206.jpg","datePublished":"2022-08-13T01:01:42+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220812005415\/en\/808160\/21\/DS_logo_portrait_format_4color_rgb_120206.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220812005415\/en\/808160\/21\/DS_logo_portrait_format_4color_rgb_120206.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/arbitrator-rules-in-favor-of-daiichi-sankyo-in-dispute-with-seagen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Arbitrator Rules in Favor of Daiichi Sankyo in Dispute with Seagen"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47269","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47269"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47269\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47269"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47269"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47269"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}